{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T21:28:31Z","timestamp":1792358911232,"version":"4.4.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejim.2020.11.014","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T02:05:56Z","timestamp":1606874756000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)"],"prefix":"10.1016","volume":"85","author":[{"given":"Maurizio Giuseppe","family":"Abrignani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Milazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Francese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Scotto di Uccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Soncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Lenarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Massimo","family":"Gulizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.11.014_bib0001","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.38947.697558.AE","article-title":"Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study","volume":"333","author":"Hallas","year":"2006","journal-title":"Br Med J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0002","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cgh.2014.11.007","article-title":"Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants","volume":"13","author":"Lanas","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0003","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jfma.2018.10.007","article-title":"Risk factors for upper gastrointestinal bleeding among aspirin users: An old issue with new findings from a population-based cohort study","volume":"118","author":"Luo","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ejim.2020.11.014_bib0004","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00535-015-1038-3","article-title":"Management of low-dose aspirin and clopidogrel in clinical practice: A gastrointestinal perspective","volume":"50","author":"Lanas","year":"2015","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0005","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/apt.14652","article-title":"Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors","volume":"47","author":"Venerito","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.11.014_bib0006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.11.014_bib0007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/MCG.0b013e318151f9d7","article-title":"Gross lower gastrointestinal bleeding in patients on anticoagulant and\/or antiplatelet therapy: Endoscopic findings, management, and clinical outcomes","volume":"43","author":"Hashash","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14740338.2017.1325870","article-title":"Risk of gastrointestinal bleeding during anticoagulant treatment","volume":"16","author":"Lanas-Gimeno","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejim.2020.11.014_bib0009","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.04.031","article-title":"Risk of Gastrointestinal Bleeding in Patients Taking Non\u2013Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis","volume":"15","author":"Miller","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamainternmed.2014.5398","article-title":"Risk of bleeding with dabigatran in atrial fibrillation","volume":"175","author":"Hernandez","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0012","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.11.014_bib0013","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.11.014_bib0014","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000350961","article-title":"Gastrointestinal adverse events after dual Antiplatelet therapy: Clopidogrel is safer than Ticagrelor, but Prasugrel data are lacking or inconclusive","volume":"126","author":"Serebruany","year":"2013","journal-title":"Cardiology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0015","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.11.014_bib0016","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.gastro.2004.05.001","article-title":"Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: A double-blind trial","volume":"127","author":"Laine","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0017","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0018","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cgh.2006.04.019","article-title":"Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications","volume":"4","author":"Lai","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0019","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0020","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5414\/CP203365","article-title":"Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system","volume":"57","author":"Fahmy","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.11.014_bib0022","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0023","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0024","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/apt.15059","article-title":"Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y12 inhibitors compared with clopidogrel","volume":"49","author":"Guo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.11.014_bib0025","first-page":"213","volume":"2017","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ejim.2020.11.014_bib0026","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1093\/eurheartj\/suy019","article-title":"Consensus Document ANMCO\/ANCE\/ARCA\/GICR-IACPR\/GISE\/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease","volume":"20","author":"Gulizia","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.ejim.2020.11.014_bib0027","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0028","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/heartjnl-2012-301632","article-title":"Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: Long-term follow-up of a cohort of patients commonly using PPI co-therapy","volume":"98","author":"Arroyo","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2020.11.014_bib0029","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10557-019-06867-z","article-title":"Examining the Risks of Major Bleeding Events in Older People Using Antithrombotics","volume":"33","author":"Nishtala","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ejim.2020.11.014_bib0030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00228-012-1386-3","article-title":"Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: A nested case-control study in a new general practice database","volume":"69","author":"De Abajo","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0031","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/jth.13316","article-title":"Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry","volume":"14","author":"Alexopoulos","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.11.014_bib0032","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/imj.13595","article-title":"Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?","volume":"47","author":"Harding","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0033","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","article-title":"Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: Experiences from SWEDEHEART registry","volume":"37","author":"Sahl\u00e9n","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0034","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","article-title":"Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function","volume":"104","author":"Edfors","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2020.11.014_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jfma.2011.11.028","article-title":"Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy","volume":"111","author":"Tsai","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ejim.2020.11.014_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221750","article-title":"Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study","volume":"14","author":"Vidyanti","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2020.11.014_bib0037","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.11.014_bib0038","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.dld.2015.01.159","article-title":"Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials","volume":"47","author":"Loffredo","year":"2015","journal-title":"Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"key":"10.1016\/j.ejim.2020.11.014_bib0039","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0040","first-page":"933","article-title":"Patient outcomes using the European label for dabigatran: A post-hoc analysis from the RE-LY database","volume":"111","author":"Lip","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2020.11.014_bib0041","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0042","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.ejim.2020.11.014_bib0043","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0044","first-page":"860","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: Part 2","volume":"38","author":"Diener","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0045","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","article-title":"Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management","volume":"23","author":"Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0046","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ejim.2020.11.014_bib0047","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.11.014_bib0048","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0049","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ajgsup.2016.3","article-title":"Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants","volume":"3","author":"Desai","year":"2016","journal-title":"Am J Gastroenterol Suppl"},{"key":"10.1016\/j.ejim.2020.11.014_bib0050","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: Population based cohort study","volume":"350","author":"Abraham","year":"2015","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.ejim.2020.11.014_bib0051","first-page":"3","article-title":"Primo anno di edoxaban in Italia: Dati di sicurezza dalla Rete Nazionale di Farmacovigilanza","volume":"2","author":"Camporese","year":"2018","journal-title":"Patient Cardiovasc Risk"},{"key":"10.1016\/j.ejim.2020.11.014_bib0052","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0016-5085(00)70004-7","article-title":"Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome","volume":"118","author":"Wolfe","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0053","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199510263331703","article-title":"A comparison of five maintenance therapies for reflux esophagitis","volume":"333","author":"Vigneri","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0054","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0055","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0056","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2018.08.035","article-title":"Use of proton pump inhibitors and risk of ischemic events in the general population","volume":"277","author":"Casula","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2020.11.014_bib0057","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.10.042","article-title":"No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002\u20132014)","volume":"154","author":"Landi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0058","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000489165","article-title":"H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review","volume":"140","author":"Almufleh","year":"2018","journal-title":"Cardiology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0059","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.ejim.2020.11.014_bib0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.2014.856883","article-title":"Antiplatelet drug interactions with proton pump inhibitors","volume":"10","author":"Scott","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.05.017","volume":"170","author":"Nicolau","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0062","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-016-0453-6","article-title":"Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: A systematic review and meta-analysis of recently published studies (2012 - 2016)","volume":"17","author":"Bundhun","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2020.11.014_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000248","article-title":"Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: An updated meta-analysis","volume":"2","author":"Cardoso","year":"2015","journal-title":"Open Heart"},{"key":"10.1016\/j.ejim.2020.11.014_bib0064","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/bdd.1795","article-title":"Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel","volume":"33","author":"Chen","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.ejim.2020.11.014_bib0065","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5009\/gnl16352","article-title":"Pantoprazole does not reduce the antiplatelet effect of clopidogrel: A randomized controlled trial in Korea","volume":"11","author":"Choi","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.ejim.2020.11.014_bib0066","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.ejim.2020.11.014_bib0067","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","article-title":"Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: Insights from the platelet inhibition and patient outcomes trial","volume":"125","author":"Goodman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.11.014_bib0068","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ehjcvp\/pvy030","article-title":"Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: A five-year experience from a single-centre observational registry","volume":"5","author":"Hoedemaker","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejim.2020.11.014_bib0069","first-page":"209","article-title":"Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome","volume":"13","author":"Yan","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0070","article-title":"Proton pump inhibitors in cardiovascular disease: Drug interactions with antiplatelet drugs","author":"W\u00fcrtz","year":"2017","journal-title":"Advances in Experimental Medicine and Biology: Springer New York LLC"},{"key":"10.1016\/j.ejim.2020.11.014_bib0071","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1053\/j.gastro.2016.08.054","article-title":"Association of Proton Pump Inhibitors With Reduced Risk of Warfarin-Related Serious Upper Gastrointestinal Bleeding","volume":"151","author":"Ray","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0072","article-title":"for the SIFA-FG, on behalf of the Italian Society of P, et\u00a0al","volume":"14","author":"Scarpignato","year":"2016","journal-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med."},{"key":"10.1016\/j.ejim.2020.11.014_bib0073","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/17512433.2017.1370369","article-title":"Drug interactions with new oral anticoagulants in elderly patients","volume":"10","author":"St\u00f6llberger","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0074","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0075","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.05.002","article-title":"Prevention of Dabigatran-Related Gastrointestinal Bleeding with Gastroprotective Agents: A Population-Based Study","volume":"149","author":"Chan","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0076","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bcp.12911","article-title":"The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies","author":"He","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0077","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and\/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0078","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0079","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.jacc.2018.03.023","article-title":"Oral Anticoagulation in Patients With Liver Disease","volume":"71","author":"Qamar","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0080","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejim.2020.11.014_bib0081","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.11.014_bib0082","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(16)32404-7","article-title":"Peptic ulcer disease","volume":"390","author":"Lanas","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2020.11.014_bib0083","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ajg.2015.98","article-title":"Peptic Ulcer Bleeding Risk. The Role of Helicobacter pylori Infection in NSAID\/Low-Dose Aspirin Users","volume":"110","author":"Sostres","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0084","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2036.2010.04415.x","article-title":"Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin","volume":"32","author":"Fletcher","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.11.014_bib0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2020.11.014_bib0086","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori Infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0087","first-page":"08","article-title":"Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis","volume":"08","author":"Sarri","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0088","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5694\/mja17.01274","article-title":"Helicobacter pylori infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis","volume":"209","author":"Ng","year":"2018","journal-title":"Med J Aust."},{"key":"10.1016\/j.ejim.2020.11.014_bib0089","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/apt.14597","article-title":"Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains","volume":"47","author":"Gatta","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2020.11.014_bib0090","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/j.gastro.2012.12.038","article-title":"Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users","volume":"144","author":"Chan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0091","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","article-title":"A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs","volume":"338","author":"Yeomans","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0092","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM199803123381105","article-title":"Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs","volume":"338","author":"Hawkey","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0093","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40266-017-0447-9","article-title":"Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands","volume":"34","author":"Chau","year":"2017","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejim.2020.11.014_bib0094","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0016-5085(94)94341-9","article-title":"Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?","volume":"106","author":"Merki","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0095","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.jacc.2015.12.068","article-title":"Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy","volume":"67","author":"Bhatt","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0096","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40256-016-0172-5","article-title":"Drug interaction between clopidogrel and ranitidine or omeprazole in stable coronary artery disease: A double- blind, double dummy, randomized study","volume":"16","author":"de Mendon\u00e7a Furtado","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2020.11.014_bib0097","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2006.07.074","article-title":"Effect of Ranitidine on the Antiplatelet Effects of Aspirin in Healthy Human Subjects","volume":"99","author":"Lev","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0098","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","article-title":"Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: Randomised phase 3 study","volume":"67","author":"Kawai","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2020.11.014_bib0099","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40261-016-0455-2","article-title":"Pharmacokinetic Drug\u2013Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men","volume":"37","author":"Sakurai","year":"2017","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.ejim.2020.11.014_bib0100","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5009\/gnl.2014.8.4.371","article-title":"Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity","volume":"8","author":"Kim","year":"2014","journal-title":"Gut Liver"},{"key":"10.1016\/j.ejim.2020.11.014_bib0101","first-page":"16","article-title":"Rebamipide does not protect against naproxen-induced gastric damage: A randomized double-blind controlled trial","author":"Gagliano-Juc\u00e1","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0102","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2010.09.010","volume":"56","author":"Abraham","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0103","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa624","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","author":"Collet","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ejim.2020.11.014_bib0104","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2020.11.014_bib0105","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","author":"Hindricks","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ejim.2020.11.014_bib0106","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/MCG.0b013e3182151be7","article-title":"A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-inflammatory drug therapy in primary care: A cross-sectional study","volume":"45","author":"Morini","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0107","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.amjcard.2015.11.007","article-title":"Acute Coronary Syndromes, Gastrointestinal Protection, and Recommendations Regarding Concomitant Administration of Proton-Pump Inhibitors (Omeprazol\/Esomeprazole) and Clopidogrel","volume":"117","author":"Lozano","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0108","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2020.11.014_bib0109","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1053\/j.gastro.2017.02.027","article-title":"Gastrointestinal Bleeding and Direct Oral Anticoagulants Amongst Patients With Atrial Fibrillation in the \u201cReal World\u201d","volume":"152","author":"Mazurek","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2020.11.014_bib0110","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2020.11.014_bib0111","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation","volume":"68","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.11.014_bib0112","first-page":"169","article-title":"The role of proton pump inhibitors in the management of upper gastrointestinal disorders","volume":"14","author":"Khan","year":"2018","journal-title":"Gastroenterol Hepatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520304246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520304246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:32:09Z","timestamp":1760607129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520304246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":112,"alternative-id":["S0953620520304246"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.11.014","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}